Acadia Pharmaceuticals

Acadia Pharmaceuticals

Type	Public
Traded as	NASDAQ: ACAD
Industry	Biopharmaceutical, Healthcare
Founded	1993
Headquarters	San Diego, CA, U.S.
Key people	Dr. Uli Hacksell CEO
Products	Pimavanserin
Revenue	$42.13M (2011)
Operating income	$22.85M (2011)
Net income	$22.76M(2011)
Total assets	108.71M (2012)
Number of employees	95 [1]
Website	[2]

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV ^[3] development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company'’s pipeline emanate from discoveries made using its proprietary drug discovery platform.

Recent Events

Acadia Pharmaceuticals extended its drug discovery and development research agreement with Allergan to March 2012. The agreement stipulates both parties will work together for the discovery of new therapeutics for glaucoma and ophthalmic conditions.^[4]

References